NCT07309367 Web-based Advance Care Planning Intervention for Patients With Kidney Failure on Dialysis: Pilot Testing of 'My Voice'
| NCT ID | NCT07309367 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Duke-NUS Graduate Medical School |
| Condition | Kidney Failure, Chronic Therapy; Hemodialysis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-02 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-10-02 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
'My Voice' is a website intervention developed to enable advance care planning (ACP) conversations for patients with kidney disease on dialysis, educate patients on their illness, help identify their goals and preferences for EOL care, and coaches them on how to speak with their HCPs and loved ones. This study aims to evaluate if 'My Voice' intervention improves quality of ACP conversations between patients and providers, and patients and family carers; improves patient's knowledge about kidney failure, engagement in ACP and preparedness for future end of life care compared to usual practices for ACP in dialysis centres.
Eligibility Criteria
Inclusion Criteria: For patients * Singapore citizens or permanent residents; aged 21 years (age of majority) or older * CKD stage 5; receiving dialysis * Identified as eligible for SIC by NKF HCPs based on one or more of the following: 1. clinical deterioration with a terminal condition or 2. intolerability to dialysis or 3. having two or more unplanned hospitalizations for renal complications in the past 6 months (from medical records); or 4. known to palliative care or under conservative care as indicated in the discharge summary or 5. poor functional status indicated by the Fragility Assessment for Elders (FIFE) score \>4 * Normal cognitive function as indicated by Mini Mental Scale Examination (MMSE) score of 24 or more (based on medical record) * Able to speak and read English, Mandarin or Malay * Agreeable to be audio-recorded Inclusion Criteria: For caregivers * Aged 21 years old and above * Family caregivers of the patients recruited i.e. Caregiver primarily involved in providing care, ensuring provision of care, and/or in making decisions regarding patient's care, with no expectation of financial compensation * Able to speak and read English, Mandarin or Malay * Have a phone and/or an electronic device with internet access. * Agreeable to be audio-recorded Exclusion Criteria: For Patients * Patients with cognitive impairment or serious mental illness will be excluded * Patients who had prior serious illness conversations (SIC) will be excluded * Are not easily contactable via mobile phone or landline Exclusion Criteria: For Caregivers * Those who are foreign domestic workers/maids * Are not easily contactable via mobile phone or landline
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07309367 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Kidney Failure, Chronic Therapy; Hemodialysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07309367 currently recruiting?
Yes, NCT07309367 is actively recruiting participants. Contact the research team at chandrika.ramky@duke-nus.edu.sg for enrollment information.
Where is the NCT07309367 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT07309367 clinical trial?
NCT07309367 is sponsored by Duke-NUS Graduate Medical School. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.